HomeNewsBusinessMarkets15400 a decisive support for Nifty; stay selective and stick to quality in small & midcaps: Mehul Kothari of AnandRathi

15400 a decisive support for Nifty; stay selective and stick to quality in small & midcaps: Mehul Kothari of AnandRathi

Kothari is bullish on UBL, Sun Pharma and Aurobindo Pharma for the short term

June 21, 2021 / 09:33 IST
Story continues below Advertisement
Mehul Kothari, AVP – Technical Research at AnandRathi
Mehul Kothari, AVP – Technical Research at AnandRathi

We have a cautious stance on the market and would advise traders to remain extremely selective while going long. It is better to keep booking longs at higher levels, Mehul Kothari, AVP – Technical Research at AnandRathi said in an interview with Moneycontrol’s Kshitij Anand. Edited excerpts:
Q) The US Fed hawkish stance rocked the boat of bulls at least for now. What led to the price action on D-Street last week?

A) The week was full of actions for the domestic markets as both bulls and bears displayed their strength following the correction in the US markets.

Although, the hawkish stance of the US Fed irked the markets. But, for our markets some profit booking was much anticipated and needed.

Story continues below Advertisement

On the whole, there was too much optimism in our markets and the crack in Dow Jones just provided the trigger for some profit booking.

Q) India Inc is showing signs of recovery, and with unlock in many states we could be heading for full recovery in the next few quarters. In case we do get a dip – what is a healthy dip which investors should not be worried about?

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show